NCT05961982: ERASE

Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study

Recruiting now NA Last updated 23 March 2026

What this trial tests

NA trial testing Chemical Ablation in Pancreatic Neoplasm in 84 participants. Currently enrolling.

Timeline

24 April 2023

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Ohio State University Comprehensive Cancer Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	84
Start date	24 April 2023
Primary completion	31 December 2027
Estimated completion	31 December 2028
Sites	1 location across United States

Drugs / interventions tested

• Chemical Ablation
• Computed Tomography
• Electronic Health Record Review
• Endoscopic Ultrasound-Guided Fine-Needle Aspiration
• Endoscopic Ultrasound-Guided Radiofrequency Ablation
• Magnetic Resonance Cholangiopancreatography
• Magnetic Resonance Imaging

Conditions studied

• Pancreatic Neoplasm — all drugs for Pancreatic Neoplasm →

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

18 and older, any sex, with Pancreatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial evaluates the safety and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for the management of patients with pancreatic tumors (including cysts) performed during recommended surveillance endoscopic ultrasound examinations. Pancreatic tumors (cysts) can progress to pancreatic cancer at rate of more than 25% per year risk. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage, and the five-year survival rate is currently less than 10%. It is projected to be the second leading cause of cancer-related mortality by the year 2030. A procedure known as radiofrequency ablation may help. Radiofrequency ablation is an established way to treat benign and cancerous tumors in the human body. In the last 5 years, radiofrequency ablation has been applied to treat precancerous tumors (including cysts) in the pancreas. This procedure implements a medical technology that destroys tumors in a much less invasive way compared to traditional surgical removal. By delivering a high-frequency alternating current, radiofrequency ablation uses electrical energy and heat to destroy cancer cells. Radiofrequency ablation is being recognized as a management option in patients with high-risk pancreatic tumors (cysts) but are not deemed surgical candidates. While surgical removal offers a chance of cure, pancreatic surgeries have 20-40% morbidity rate (short and long-term complication) and a 1-2% mortality rate in patients who are surgical candidates. Furthermore, radiofrequency ablation can potentially decrease the need for frequent imaging/surveillance of the pancreatic tumor (cyst). In patients with immediate prohibitive, but reversible risks for surgery, radiofrequency ablation of a high-risk tumors (cysts) can potentially prevent further progression of the lesion and bridge the time before the need for surgical resection.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation.
   Moond V, Maniyar B, Harne PS, Bailey-Lundberg JM, et al · · 2024 · cited 6× · PMID 39351436 · DOI 10.37349/etat.2024.00263
2. Endoscopic ultrasound-guided radiofrequency ablation for large branch-duct intraductal papillary mucinous neoplasms: Safety and efficacy trial.
   Krishna SG, Park E, Rath J, Shah Z, et al · · 2026 · PMID 41584732 · DOI 10.1055/a-2778-8145